Prospective Study of Liposomal Bupivacaine for Pain Control of Split Thickness Skin Graft Donor Sites
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Donor site pain study comparing post-operative donor site pain and opioid consumption after use of Lidocaine, Liposomal Bupivicaine or regional nerve block for split thickness skin graft harvesting in patients with less than 20% TBSA burn wounds and less than %5 Deep partial or full thickness burn wounds.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Spanish/English speaking
• \<20%TBSA; \<5% TBSA deep partial or full thickness burns
Locations
United States
Kansas
The University of Kansas Health System
RECRUITING
Kansas City
Contact Information
Primary
Jessica Reynolds, BSN
jreynolds11@kumc.edu
913-588-0044
Backup
Dhaval Bhavsar, MD
dbhavsar@kumc.edu
913-588-2000
Time Frame
Start Date: 2019-03-18
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 75
Treatments
Experimental: Group 1
Liposomal Bupivicaine (266mg/20ml) will be diluted into Lactated Ringer solution (280 ml) and injected once intra-operatively subcutaneously before donor site harvesting
Active_comparator: Group 2
Lidocaine (50 mg/50 ml) will be diluted into Lactated Ringer (1000ml) and injected once subcutaneously before donor site harvesting
Experimental: Group 3
Subjects will receive regional anesthesia with a bupivacaine nerve block; either a fascia iliaca, lateral femoral cutaneous, or femoral nerve block based on the proposed donor site location
Related Therapeutic Areas
Sponsors
Leads: University of Kansas Medical Center